Crosswalk Therapeutics
Crosswalk Therapeutics: Pursuing Functional Cures for Rare Diseases and Beyond
We are a seed-stage biotech company dedicated to relentlessly pursuing functional cures for rare disease patients and their families. With an initial focus on rare diseases, we aim to expand our scope to include genetically defined common diseases in the future.
patient-centric innovation
The Team
Crosswalk is founded by a team with extensive experience in rare diseases, having worked at TKT, Shire, Dyax, Baxter, Baxalta, and Takeda. Collectively, the team has spent hundreds of years developing therapies for rare disease patients, achieving significant success in their previous roles.
Genetically Validated Targets
Over 80% of rare diseases have genetic origins. Our strengths include providing functional replacements for loss-of-function diseases and engineering solutions for toxic gain-of-function diseases. By focusing on clinically identified and pre-clinically validated targets, we enhance the likelihood of program success.
Diversity of Modality Expertise
Our approach is technology-neutral. We focus on the modality best suited for the therapeutic requirements, while also considering patient convenience.
Therapeutic Areas
We have developed expertise in multiple therapeutic areas, including lysosomal storage diseases, inborn errors of metabolism, benign hematology, and immunology. Our diverse experiences enable us to quickly enter new domains and leverage a broad perspective to bring innovative solutions to existing problems.